5AM Venture Management LLC Purchases 569,782 Shares of Protara Therapeutics, Inc. $TARA

5AM Venture Management LLC boosted its stake in shares of Protara Therapeutics, Inc. (NASDAQ:TARA) by 71.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,369,782 shares of the company’s stock after buying an additional 569,782 shares during the period. Protara Therapeutics makes up about 2.3% of 5AM Venture Management LLC’s investment portfolio, making the stock its 16th largest holding. 5AM Venture Management LLC’s holdings in Protara Therapeutics were worth $7,301,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. UBS Group AG increased its holdings in shares of Protara Therapeutics by 44.2% in the 4th quarter. UBS Group AG now owns 1,215,537 shares of the company’s stock worth $6,479,000 after purchasing an additional 372,463 shares in the last quarter. Maven Securities LTD bought a new stake in shares of Protara Therapeutics in the 4th quarter worth $4,022,000. Oppenheimer & Co. Inc. increased its holdings in shares of Protara Therapeutics by 8.1% in the 4th quarter. Oppenheimer & Co. Inc. now owns 223,767 shares of the company’s stock worth $1,193,000 after purchasing an additional 16,794 shares in the last quarter. Almanack Investment Partners LLC. increased its holdings in shares of Protara Therapeutics by 76.2% in the 4th quarter. Almanack Investment Partners LLC. now owns 23,782 shares of the company’s stock worth $127,000 after purchasing an additional 10,288 shares in the last quarter. Finally, Invesco Ltd. bought a new stake in shares of Protara Therapeutics in the 2nd quarter worth $73,000. Institutional investors own 38.13% of the company’s stock.

Protara Therapeutics Stock Performance

NASDAQ TARA opened at $4.07 on Thursday. The company has a market capitalization of $228.73 million, a PE ratio of -3.04 and a beta of 1.45. The business’s fifty day moving average is $4.83 and its 200 day moving average is $5.48. Protara Therapeutics, Inc. has a fifty-two week low of $2.77 and a fifty-two week high of $7.82.

Protara Therapeutics (NASDAQ:TARA) last released its earnings results on Wednesday, May 13th. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.05. On average, sell-side analysts forecast that Protara Therapeutics, Inc. will post -1.45 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on TARA. Wall Street Zen upgraded Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. JPMorgan Chase & Co. dropped their price target on Protara Therapeutics from $27.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, May 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Tuesday, April 21st. Oppenheimer raised their price target on Protara Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 20th. Finally, HC Wainwright restated a “buy” rating on shares of Protara Therapeutics in a research note on Wednesday, May 20th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $26.25.

Insider Buying and Selling

In other Protara Therapeutics news, insider Jacqueline Zummo sold 22,598 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $5.26, for a total transaction of $118,865.48. Following the sale, the insider directly owned 95,961 shares of the company’s stock, valued at $504,754.86. This trade represents a 19.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.60% of the stock is currently owned by corporate insiders.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.